

GLOBAL LIFE SCIENCES FUND

I2 USD ISIN IE0002141913

Investment objective

The Fund aims to provide capital growth over the long term. Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.

For the fund's investment policy, refer to the Additional fund information on page 3.


Past performance does not predict future returns.

Performance (%)

| Returns | Cumulative | | | | Annualised | | | |
|----------------|------------|---------|--------|--------|------------|--------|---------|----------------------------|
| | 1 Month | 3 Month | YTD | 1 Year | 3 Year | 5 Year | 10 Year | Since inception (31/03/00) |
| I2 USD (Net) | -0.92 | 13.74 | -3.59 | -3.59 | 8.18 | 10.75 | 14.44 | 8.04 |
| Index | -1.18 | 13.14 | -5.41 | -5.41 | 8.75 | 10.20 | 12.03 | 7.72 |
| Sector | -0.26 | 11.61 | -13.91 | -13.91 | 3.58 | 5.51 | 9.34 | 6.24 |
| I2 USD (Gross) | — | — | — | — | — | 12.54 | 16.34 | 9.86 |
| Target | — | — | — | — | — | 12.41 | 14.27 | 9.87 |

Cumulative growth - USD

31 Dec 2017 — 31 Dec 2022



12 month rolling

| | Dec 2021- Dec 2022 | Dec 2020- Dec 2021 | Dec 2019- Dec 2020 | Dec 2018- Dec 2019 | Dec 2017- Dec 2018 |
|--------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| I2 USD (Net) | -3.59 | 5.60 | 24.37 | 28.04 | 2.76 |
| Index | -5.41 | 19.80 | 13.52 | 23.24 | 2.51 |
| Sector | -13.91 | 7.12 | 20.53 | 21.80 | -3.40 |

Performance is on a net of fees basis, with gross income reinvested. Source: at 31/12/22. © 2023 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. Performance/performance target related data will display only where relevant to the share class inception date and annualised target time period. **The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** Source for target returns (where applicable) - Janus Henderson Investors.

Fund details

| | |
|--------------------|------------------------------|
| Inception date | 31 March 2000 |
| Total net assets | 3.92bn |
| Asset class | Equities |
| Domicile | Ireland |
| Structure | Irish Investment Company |
| Base currency | USD |
| Index | MSCI World Health Care Index |
| Morningstar sector | Sector Equity Healthcare |

Share class information

| | |
|----------------------------|---------------|
| Inception date | 31 March 2000 |
| Distribution type | Accumulation |
| Currency | USD |
| Minimum initial investment | 1,000,000 |

Portfolio management

Andy Acker, CFA Manager since 2007

Ratings

Overall Morningstar Rating™ ★★★★★

For the source and information on ratings shown above, refer to page 3.

Characteristics

| | |
|-----------------------------------|----------|
| Number of holdings: Equity issues | 127 |
| Annual turnover (1yr trailing) | 24.67% |
| Weighted average market cap | 133.71bn |
| Price-to-book ratio | 4.54 |
| Price-to-earnings ratio | 17.04 |

Risk statistics (3 years)

| | Fund | Index |
|--------------------|-------|-------|
| Beta | 0.96 | 1.00 |
| Standard deviation | 17.26 | 16.35 |
| Sharpe ratio | 0.43 | 0.49 |

Top holdings (%)

| | Fund |
|------------------------------|--------------|
| UnitedHealth Group Inc | 6.57 |
| AstraZeneca PLC | 4.39 |
| AbbVie Inc | 3.89 |
| Eli Lilly & Co | 2.99 |
| Merck & Co Inc | 2.98 |
| Novartis AG (ADR) | 2.68 |
| Sarepta Therapeutics Inc | 2.60 |
| Sanofi | 2.59 |
| Abbott Laboratories | 2.34 |
| Thermo Fisher Scientific Inc | 2.32 |
| Total | 33.35 |

References made to individual securities should not constitute or form part of any offer or solicitation to issue, securities mentioned in the report.

Market capitalisation of equity holdings (%)

| | Fund | Index |
|------------------|-------|-------|
| Over \$100B | 45.70 | 62.29 |
| \$50B to \$100B | 9.65 | 15.61 |
| \$10B to \$50B | 23.16 | 19.95 |
| \$5B to \$10B | 6.34 | 1.89 |
| \$1B to \$5B | 9.50 | 0.13 |
| \$500M to \$1B | 2.38 | — |
| \$250M to \$500M | 0.23 | — |
| \$100M to \$250M | 0.16 | — |
| Under \$100M | 0.04 | — |
| N/A | 1.95 | 0.13 |

Sector allocation (%)

| | Fund | Index |
|--------------------------------|-------|-------|
| Pharmaceuticals | 31.97 | 40.78 |
| Biotechnology | 31.90 | 14.60 |
| Managed Health Care | 12.09 | 10.33 |
| Health Care Equipment | 11.95 | 14.55 |
| Life Sciences Tools & Services | 6.68 | 10.16 |
| Health Care Supplies | 2.36 | 2.45 |
| Health Care Distributors | 1.24 | 1.59 |
| Health Care Services | 0.85 | 4.06 |
| Health Care Technology | 0.07 | 0.48 |

Top countries (%)

| | Fund | Index |
|--------------------|-------|-------|
| United States | 79.69 | 73.41 |
| Switzerland | 4.94 | 7.24 |
| United Kingdom | 4.72 | 4.05 |
| Denmark | 2.99 | 3.68 |
| France | 2.59 | 2.60 |
| Belgium | 1.63 | 0.42 |
| Japan | 1.46 | 4.26 |
| Germany | 0.59 | 1.85 |
| China | 0.46 | — |
| Korea, Republic Of | 0.04 | — |

Regions (%)

| | Fund | Index |
|-----------------------|-------|-------|
| North America | 79.69 | 73.41 |
| Europe | 17.46 | 20.42 |
| Japan | 1.46 | 4.26 |
| Asia/Pacific Ex Japan | 0.50 | 1.77 |

Codes

| | |
|-----------|--------------|
| ISIN | IE0002141913 |
| Bloomberg | JANGLI2 ID |
| Cusip | G50110207 |
| SEDOL | 0214191 |
| WKN | 935600 |
| Valoren | 1060717 |

Fees & charges (%)

| | |
|--------------------------------|------|
| Annual management charge (AMC) | 1.50 |
| Ongoing charge (OCF) | 1.57 |

All ongoing charges stated are as per latest published report and accounts. Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at www.janushenderson.com. Under some circumstances initial charges may apply. Please refer to the Prospectus for more details.

Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. This is an Irish Investment Company regulated by the Central Bank of Ireland. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations. A short-term trading fee may be applied upon exiting the fund as per the prospectus. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund.

Investment policy

The Fund invests at least 80% in shares (also known as equities) of companies, of any size, with a life sciences orientation, in any country. The Fund may also invest in other assets including cash and money market instruments. The investment manager may use derivatives (complex financial instruments) to reduce risk, to manage the Fund more efficiently, or to generate additional capital or income for the Fund. The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The investment manager has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

Investment strategy

The investment manager looks to identify innovative healthcare companies addressing high unmet medical needs across fields including biotechnology, pharmaceuticals, healthcare services and medical technology. The team understands that success of drug development is binary in nature, creating wide disparities between winners and losers. The investment process leverages proprietary statistical models to analyse the probability of a company's success, focusing on products they believe can overcome the rigours of clinical development. Additional tools, such as physician surveys and prescription models, attempt to more accurately predict commercial viability.

Fund specific risks

When the Fund, or a hedged share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency, the hedging strategy itself may create a positive or negative impact to the value of the Fund due to differences in short-term interest rates between the currencies. The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider. Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result. Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses. If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified. The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events. The Fund may use derivatives towards the aim of achieving its investment objective. This can result in 'leverage', which can magnify an investment outcome and gains or losses to the Fund may be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations. If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share/unit class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates. Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.

Source for fund ratings/awards

Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star. Overall Morningstar Rating™ is shown for Janus Henderson share classes achieving a rating of 4 or 5. Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to global.morningstar.com/managerdisclosures.

Glossary

Beta

Beta measures how a fund or security moves in relationship to the overall market. A market has a beta of 1. If the fund/security's beta is more than 1, it moves more than the market, while a beta lower than 1 means it moves to a lesser extent than the market. A negative beta could mean the fund/security moves in the opposite direction to the market.

Price-to-book (P/B) ratio

A financial ratio used to value a company's shares. It is calculated by dividing a company's market value (share price) by the book value of its equity (value of the company's assets on its balance sheet). A P/B value <1 can indicate a potentially undervalued company or a declining business. The higher the P/B ratio, the higher the premium the market is willing to pay for the company above the book (balance sheet) value of its assets.

Price-to-earnings (P/E) ratio

A popular ratio used to value a company's shares, compared to other stocks, or a benchmark index. It is calculated by dividing the current share price by its earnings per share.

Sharpe ratio

This measures a portfolio's risk-adjusted performance. A high Sharpe ratio indicates a better risk-adjusted return. The ratio is designed to measure how far a portfolio's return can be attributed to fund manager skill as opposed to excessive risk taking.

Standard deviation

A statistic that measures the variation or dispersion of a set of values/data. A low standard deviation shows the values tend to be close to the mean while a high standard deviation indicates the values are more spread out. In terms of valuing investments, standard deviation can provide a gauge of the historical volatility of an investment.

Weighted average market cap

The average market capitalisation of a holding, weighted by the size of that position in a portfolio or index.

Janus Henderson
— INVESTORS —

FOR MORE INFORMATION PLEASE VISIT JANUSHENDERSON.COM

ESG integration is the practice of incorporating material environmental, social and governance (ESG) information or insights in a non-binding manner alongside traditional measures into the investment decision process to improve long term financial outcomes of portfolios. This product does not pursue a sustainable investment strategy or have a sustainable investment objective or otherwise take ESG factors into account in a binding manner. ESG related research is one of many factors considered within the investment process and in this material we seek to show why it is financially relevant. For Qualified investors, institutional,

wholesale client use only. Outside of Switzerland, this document is for Institutional/sophisticated investors / accredited investors qualified distributors use only. Issued in: (a) Europe by Janus Henderson Investors International Limited ("JHILL"), authorised and regulated in the U.K by the Financial Conduct Authority, Janus Henderson Investors Europe S.A. (reg no. B22848) is incorporated and registered in Luxembourg with registered office at 2 Rue de Bitbourg, L-1273 Luxembourg and authorised by the Commission de Surveillance du Secteur Financier and (b) Dubai by JHILL authorised and regulated by the Dubai Financial Services Authority as a Representative Office. JHILL acts as lead investment adviser to Janus Henderson Capital Funds plc (JHCF). Janus Henderson Investors US LLC, Janus Henderson Investors (Singapore) Limited, INTECH Investment Management LLC, Janus Henderson Investors UK Limited, Kapstream Capital pty Limited will act as sub-adviser to JHILL. JHCF is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying/facilities agents, it should be read carefully. This is a marketing communication. Please refer to the prospectus of the UCITS and to the KIID before making any final investment decisions. For sustainability related aspects please access Janushenderson.com. The Prospectus and KIID are also available from www.janushenderson.com Portfolio Holdings are subject to change without notice. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. This document is not for use in any country or with any individuals who are not eligible to invest in this Fund. JHCF is not regulated by the Financial Conduct Authority and the protections available under the Financial Services Compensation Scheme and the Financial Ombudsman Service will not be available in connection with an investment. Past performance does not predict future returns. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This document is provided for information purposes only and is not an invitation to purchase any JHCF Funds. Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this presentation and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. The performance data does not take into account the commissions and costs incurred on the issue and the redemption of shares. This communication does not constitute an offer or a recommendation to sell or purchase any investment. In Ireland the Facilities Agent is Citi Fund Services (Ireland) Limited .Its custodian is JP Morgan Bank (Ireland) Plc. The Custodian in Spain is Santander Securities Services, S.A. The last share prices can be found on www.fundinfo.com. Copies of the Fund's prospectus, Key Investor Information Document, articles of incorporation, annual and semi-annual reports are available in English and other local languages as required from www.janushenderson.com. These documents can also be obtained free of cost from the local offices of Janus Henderson Investors: 201 Bishopsgate, London, EC2M 3AE for UK. The summary of Investors Rights is available in English from <https://www.janushenderson.com/summary-of-investors-rights-english>. Janus Henderson Investors Europe S.A.may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation. Not for onward distribution. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. Janus Henderson, Knowledge Shared and Knowledge Labs are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc.